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672Front-line High-Dose Chemotherapy with Rituximab
Showed Excellent Long-Term Survival in Adults with
Aggressive Large B-Cell Lymphoma: Final Results
of a Phase II GOELAMS Study
Marie-Sarah Dilhuydy,1 Thierry Lamy,2 Charles Foussard,3 Remy Gressin,4
Philippe Casassus,5 Eric Deconninck,6 Christine Le Maignan,7 Diane Damotte,8
Noel Milpied1 for the Groupe Ouest-Est des Leucemies et Autres Maladies
du Sang (GOELAMS)To evaluate the effect of rituximab in poor-prognosis patients with diffuse large B-cell lymphoma (DLBCL),
a multicenter phase II trial combining rituximab with chemotherapy followed by high-dose therapy (HDT)
with autologous stem cell transplant was conducted by the Groupe Ouest–Est des Leucemies et des Autres
Maladies du Sang (GOELAMS). Patients were aged 18 to 60 years, with newly diagnosed CD20-expressing
DLBCL, and at least 2 adverse risk factors as defined by the age-adjusted International Prognostic Index (aa-
IPI). The treatment consisted of 2 courses of high-dose CHOP-like regimen on day 1 and 15 and 1 course of
methotrexate and cytarabine on day 36. Four doses of rituximab (375 mg/m2) were infused on days 1, 15, 22,
and 36. For patients who achieved at least a partial remission (PR), HDT followed by autologous stem cell
transplant was performed on day 66. From April 2002 to May 2003, 42 patients were eligible. Half were
high aa-IPI risk patients. Thirty-eight patients (90%) completed the treatment. Treatment-related mortality
was 7% and no toxic death was related to rituximab. Complete response rate after the end of the full treat-
ment was 67%. With a median follow-up of 66 months, event-free survival and overall survival rates were
55% and 74%, respectively. Median survival was not reached. First-line HDTwith rituximab offers promising
results for young adults with intermediate high or high aa-IPI high-grade lymphoma. Immediate and late tox-
icities were low. This treatment is being randomly compared prospectively with CHOP-14-rituximab in
young adults with DLBCL (GOELAMS 075 trial).
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The outcome of patients newly diagnosed with ag-
gressive non-Hodgkin lymphoma (NHL) identified
as ‘‘high’’ and ‘‘intermediate-high’’ (IH) risk groups
according to the international prognostic index (IPI)
is still unsatisfactory with a long-term survival around
50% [1]. The CHOP (cyclophosphamide [Cy], doxo-
rubicin, vincristine, and prednisone) regimen was the
standard initial treatment for these aggressive lympho-
mas. The development of rituximab, a chimeric
anti-CD20 monoclonal antibody, represents a revolu-
tionary advance in the therapy of hematologic malig-
nancies. The addition of rituximab to CHOP
chemotherapy has achieved impressive survival benefits
in elderly patients with untreated diffuse large B-cell
lymphoma compared with CHOP alone [2,3].
Improved response and survival were obtained with
Biol Blood Marrow Transplant 16:672-677, 2010 673Excellent Result of Up-front HDTwith Rituximab in Aggressive NHLminimal additional toxicity, suggesting that immuno-
chemotherapy could be the new standard of care in ag-
gressive NHL [2-4].
High-dose therapy (HDT) followed by autologous
stem cell transplantation (ASCT) has become the stan-
dard treatment for relapsed or refractory patients. The
role for HDT as frontline therapy for IH and high-risk
IPI patients remains unclear, but several trials have
provided encouraging results [5-7].
HDTwith ASCTwas demonstrated to be superior
to CHOP in young adults with IH age-adjusted IPI
(aaIPI) in a previous randomized Groupe Ouest-Est
des Leucemies et des Autres Maladies du Sang
(GOELAMS) study [8]. Since the trial was initiated
in 1994, rituximab was not included in the therapeutic
strategy. In an attempt to improve outcome, a prospec-
tive trial (GOELAMS 074 study) was designed to eval-
uate the feasibility and the efficacy of adding rituximab
to HDT in IH and high-risk patients below the age of
60 years.METHODS
Patients
To be included, patients had to be aged from 18 to
60 years with previously untreated histologically
proven CD 20 positive aggressive lymphoma, Ann
Arbor stage III or IVor a stage IIwith bulky disease (tu-
mor mass more than 7 cm at the largest diameter); an
IH or high-risk stage (ie, 2 or 3 of the possible adverse
prognostic factors (regarding tumor stage, serum lac-
tate dehydrogenase concentration, and performance
status) according to the aaIPI [1]; and absence of under-
lying organ dysfunction precluding the use of anthracy-
clins or high-dose chemotherapy. Patients with
transformed low-grade, lymphoblastic, mantle-cell,
central nervous system primary lymphoma or Burkitt’s
lymphoma, infection with the human immunodefi-
ciency virus, and patients with a history of serious aller-
gic events were excluded. The trial was approved by the
ethics committee of the Centre Hospitalier Universi-
taire de Nantes, Nantes, France, and all patients gave
written informed consent.
Pretreatment Evaluation
In addition to physical examination, routine labora-
tory tests, bonemarrow biopsy, and thoraco abdominal
computed tomography were performed within 30 days
before inclusion. Diagnostic slides were reviewed cen-
trally by 2 pathologists (M.F. Gontier andD.Damotte)
at time of inclusion.
Treatment and Stem Cell Collection
Patients received 2 courses of the following 15 days
apart: rituximab 375 mg/m2 (Mabthera, suppliedfree of charge by Roche, France), Cy 1200 mg/m2 in-
travenously (i.v.), epirubicin 100 mg/m2 i.v., vindesine
3 mg/m2 i.v. on day 1 and 80 mg/m2 of prednisone
orally or i.v. on day 1 through day 5 (R-CEEP regi-
men). Filgrastim 5 mg/kg/day (Amgen, Neuilly-
sur-Seine, France) i.v. or subcutaneously was started
on day 5 of each course. Peripheral blood stem cells
were collected by leukaphereses during the hemato-
logic recovery phase after the second course of
CEEP. The goal was to obtain at least 2 million hema-
topoietic stem cells per kilogram for cryopreservation.
A fourth infusion of rituximab was administered on
day 36, followed by a combination of methotrexate
3 g/m2 i.v. on day37 and cytarabine 100mg/m2 i.v. given
by continuous infusion from day 37 to day 41 following
CEEP courses.
The response was evaluated after the methotrex-
ate-aracytine protocol when the neutrophil count
had recovered. The patients without partial response
after chemotherapy were treated off-study and the
clinical courses were documented. Patients who had
at least a partial response underwent HDT. The con-
ditioning regimen started on day 66. This BEAM reg-
imen was a combination of carmustine (300 mg/m2 i.v.
on day 66), etoposide (400 mg/m2 i.v. from day 67 to
day 71), cytarabine (400mg/m2 by continuous infusion
from day 67 to day 71), and melphalan (140 mg/m2 i.v.
on day 72). Peripheral blood stem cells were infused
within 36 to 48 hours after melphalan administration
on day 73 or 74. Granulocyte colony-stimulating fac-
tor was given 5 days after transplantation until neutro-
phil count recovery. Response was again evaluated
30 days after HDT.
Follow-up procedures included a physical examina-
tion and a thoraco abdominal computed tomography
every 3 months for the first 2 years and then every
6 months. Relapse, serious adverse events and deaths
were recorded.Assessment of Response
A complete response (CR) was defined as the
disappearance of all measurable or evaluable diseases,
signs, or symptoms related to the tumor. An uncon-
firmed complete response (CRu) was defined as
a CR with the persistence of some radiologic abnor-
malities that had to have regressed in size by at least
70%. A partial response (PR) was defined as a reduc-
tion of at least 50% in the largest diameter of every
measurable lesion, even if bone marrow involvement
persisted on the intermediate evaluation [9]. The
procedures used to evaluate responses were the
same as those used for staging at diagnosis. A residual
lesion biopsy was not mandatory at the time of either
the intermediate evaluation or the final evaluation.
Positron-emission tomography was not routinely
performed.
Table 1. Characteristics of the 42 Patients
N (%)
Sex
Female 18 (43)
Male 24 (57)
Median age 50 (18-60)
Performance status
0-1 18 (43)
2 19 (45)
3 4(10)
4 1 (2)
Ann Arbor stage
II 5 (12)
III 6 (14)
IV 31 (74)
Age-adjusted IPI
IH 23 (55)
high 19 (45)
Marrow involvement 11 (26)
LDH > N 38 (90)
IPI indicates International Prognostic Index; LDH, lactate dehydrogenase.
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The primary endpoint was CR/CRu rate after
immunochemotherapy. Secondary end points were
the response rate at the end of treatment, the overall
survival (OS) and event-free survival (EFS), the inci-
dence of adverse effects with the addition of rituximab
and the feasibility of harvesting stem cells after
2 courses of chemotherapy. In addition, prognostic
factors for CR, OS, and EFS were sought. For OS
and EFS, the end of analysis was December 2008.
According to GOELAMS rates of inclusion, the
study was planned for a 2-year recruitment leading to
a total of 40 to 45 patients. The CR/CRu rate was
40% in the previous GOELAMS 072 trial without
rituximab. A 55% CR/CRu rate with the addition of
rituximab appears to be valid. With a least 40 patients
included and a CR/CRu rate of 55%, the lower limit of
the 95% confidence interval (CI) of the CR/CRu rate
would be .40%.Statistical Analysis
The CR/CRu rate after immunochemotherapy
was plotted as a percentage for all patients included.
At the end of treatment, the response rate was reported
as a percentage among all included patients who
underwent HDT and ASCT. OS and EFS were calcu-
lated according to the Kaplan-Meier method. Survival
was measured from the time of inclusion to death from
any cause or the date of last contact. EFS was calcu-
lated from the time of inclusion to the first event
among the following: the absence of at least a PR on
the intermediate evaluation, progression, relapse, and
death. Analysis was performed on an intention-to-treat
basis for patients who had data that could be evaluated.
Multivariate analysis of CRwas performed with the lo-
gistic regression model. Multivariate analysis of OS
and EFS was performed with the proportional hazards
model. The study was designed by the GOELAMS
scientific committee. The data were collected by the
principal investigator at each participating center,
checked for accuracy by GOELAMS research assis-
tants, and sent to the centralized data base in Nantes.
The academic investigators had full access to the
data. Statistical analysis was performed with SPSS
software (version 12.0).RESULTS
Patients
Between April 2002 and May 2003, 42 patients
were enrolled in 16 GOELAMS centers in France.
The median age of the patients was 50 years. Table 1
lists the pretreatment characteristics of these 42 pa-
tients who were well distributed between IH (n 5 23)and high risk (n 5 19). Only 5 patients were stage II
with bulky disease.
Feasibility and Response to Treatment
Patients’ flowcharts are reported in Figure 1. The
induction treatment was completed in 38 (90%)
patients. Toxic deaths led to treatment withdrawal in
3patients (1 pulmonary embolism,1multiorgan failure,
and 1 unknown cause) and 1 patient refused HDT.
A total of 23 patients (55%; [95% CI 42%-72%])
achieved CR and 7 achieved PR (16%), leading to an
overall response rate of 71% with chemotherapy be-
fore HDT. At the end of the full treatment, 28 patients
(67%; [95% CI 50%-79%]) achieved CR/CRu. The
other 8 patients had either progressive (3 patients) or
stable disease (5 patients).
The patient who refused HDT was treated with
conventional chemotherapy and is still inCR.Concern-
ing the 8 patientswhodid not undergoHDTbecause of
progressive or stable disease, 2 patients died before
rescue treatment and a rescue protocol was performed
in 6 others. These 6 patients were still in CR after
chemotherapy only (3 patients) or HDT (3 patients).
Stem Cell Collection and Response to HDT/
ASCT
Leukaphereseswere performed in all 30 responders
and in a total of 34 patients. The median number of
CD341 collected cells was 11.7  106/kg (range: 4.2-
102  106/kg). For the 8 remaining patients, stem cell
collection was not performed because of death (3 pa-
tients), progressive disease (1 patient), patient refusal
(1 patient), and collection failure (3 patients).
There was no HDT-related death and median
hospitalization duration was 21 days (range: 12-31).
Feasibility of the induction treatment up to stem
cell collection was 71% [95% CI 58%-85%]). On
1 toxic death
42 inclusions
1 consent wtihdrawal
1 toxic death
1 toxic death
N=38
R-CEEP #1
N=42
R-CEEP #2
N=40
R-MTX-AraC
N=39
SD or PD
N=8
HDT BEAM
N=30
Complete response
N=23
Response evaluation
Partial response
N=7
Figure 1. Flowchart of patients included in the GOELAMS 074 study.
CEEP, cyclophosphamide, epirubicin, vindesine, prednisone; HDT,
high-dose therapy; BEAM, carmustine, etoposide, cytarabine, melphalan.
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(67%; [95% CI 50%-79%]), 3 had PR, and 8 had less
than PR or progression at the end of the full treatment.Relapse
Eight patients relapsed after HDT with a median
time to relapse of 7.1 months (range: 2.2-47). At the
end of the full treatment, 7 of these patients had CR
and 1 had PR. All patients received rescue chemother-847260483624120
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Figure 2. (A) In an intention-to-treat analysis, 5-year OS is 74%. Median surviapy. Two patients were in second complete response
and 6 died because of disease progression.Survival
With a median follow-up of 66 months for the
entire cohort, the estimated rates (6SD) of 5-year
OS and EFS rates were 74% 6 4% and 55% 6 5%,
respectively (Figure 2A and B). Median survival was
not reached. According to the aaIPI, the 5-year OS
and EFS were 82% and 56%, respectively, for IH
patients and 63% and 53% for high-risk patients.
The difference was not statistically significant
(Figure 3A and B). Five-year OS was 58% for the 12
patients who went off the protocol.
Among the 42 patients, 11 died.The causes of death
were disease progression for 8 patients and treatment-
related toxicity for 3 of them, resulting in a treatment-
related mortality (TRM) of 7%.Prognostic Parameters
On univariate analysis, OS was independently
affected by performance status (P5 .05). Risk accord-
ing to aaIPI and age were not significant factors.
Performance status, lactate dehydrogenase level, age,
and risk according to aaIPI were not retained in the
multivariate analysis. On univariate and multivariate
analysis, complete response rate was not affected by
any of the above-mentioned factors.Toxicity
No death was directly related to the addition of
rituximab. Toxic deaths caused treatment withdrawal
in 3 patients (one multiorgan failure, 1 pulmonary
embolism, and 1 toxic death not otherwise specified
[NOS]), leading to a TRM of 7%.
With amedian follow-upof 66months for the entire
cohort, only 2 serious events occurred: 1 lung cancer and
1 cardiac dysfunction following an anthracyclin-based
regimen (R-CHOP) for relapse. Both patients are
still alive in complete remission. No myelodysplastic
syndrome occurred.847260483624120
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val is not reached. (B) In an intention-to-treat analysis, 5-year EFS is 55%.
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Figure 3. (A) Five-year OS according to aa-IPI is 82% for IH and 63% for high-risk patients (not statistically significant). (B) Five-year EFS according to
aa-IPI is 56% for IH and 53% for high-risk patients (not statistically significant).
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The GOELAMS group has shown that HDTwith
ASCT is superior to CHOP in young adults with HI
aa-IPI lymphoma [8]. These data are now confirmed
after an extended follow up of 10 years. Among pa-
tients with HI aa-IPI lymphoma, 10-year OS was
57% for the HDT arm versus 28% for the CHOP
arm (P5 .015) [10]. Because these trials were initiated
in 1994, rituximab was not included in the therapeutic
strategy.
The present trial was designed to test the efficacy
and feasibility of adding rituximab to chemotherapy
before HDT/ASCT. The main objective was to evalu-
ate CR/CRu after immunotherapy. Most of the pa-
tients (90%) completed their immunochemotherapy.
In the intent-to-treat population, CR was obtained in
23 of 42 patients (55%) before HDT and ASCT pro-
cedure. This CR rate is exactly the expected CR rate
and validates the interest of adding rituximab to
conventional chemotherapy before HDT and ASCT.
Rituximab was added to chemotherapy without
any additional toxicity occurring. All planned infusions
were performed and no chemotherapy dose decrease
was necessary. There was no leukapheresis failure for
responder patients and the TRM was 7%. Thirty of
42 patients (71%) received all treatment procedures,
including HDT and ASCT, thereby highlighting the
good feasibility of this treatment in poor-prognosis pa-
tients. These results are similar to those in 2 ItalianGI-
TIL trials, with 75% of patients receiving the whole
treatment and a TRM of between 3% and 4.5% in
the HDT with rituximab arm [11,12].
Although they concern only 42 patients, our results
compare favorably with previous findings. These re-
sults compare favorably with those reported in other
series after HDT in patients with better prognosis. Us-
ing immunochemotherapy followed by HDT-ASCT
[13], the Groupe d’Etudes des Lymphomes de l’Adulte
(GELA) obtained similar results to those in the present
study. Nevertheless, only 22% of their study popula-
tion was aaIPI high-risk patients versus 45% in our
cohort, which represents twice as many patients witha very poor prognosis. The GITIL used a very high-
dose regimen containing rituximab, with high-dose
Cy, high-dose AraC, 3 peripheral stem cell infusions,
and involved-field radiotherapy on area of residual le-
sions. Using this very heavy schedule, they obtained
similar results, with a 4-year OS of 76%. Late toxicity
was higher than ours [11].
Moreover, with a median follow-up of 10 years,
2 previous GOELAMS studies without rituximab
demonstrated a worse CR and OS rate for IH and
high-risk patients. For IH patients, the GOELAMS
072 study HDT arm showed a CR of 40% only, re-
sulting in a worse OS (57%) [10]. In the GOELAMS
073 study evaluating up-front tandem HDT for
high-risk patients, 10-year OS, and EFS were 51%
and 53%, respectively (H. Monjanel, unpublished
data).
The 5-year OS of 74% suggests the very good
value of first-line HDT with rituximab for these
poor-prognosis patients. Moreover, there was a clear
plateau in both the OS and PFS curves 57 months after
transplantation.
The toxicity profile was similar to that observed
with chemotherapy and HDT/ASCT without rituxi-
mab. Three patients (7%) died as a result of treat-
ment-related complications, which is in line with
prior experience [11,14].
With a very long follow-up, few late complications
were noted. Only 1 patient presented with a secondary
malignancy and another had cardiac complications.
Both patients are alive, so there was no delayed toxic
death. No myelodysplasia or delayed neutropenia
were observed. After a 10-year follow-up, the late tox-
icity was similar in the HDT arm of the GOELAMS
072 study (nomyelodysplasia, 2% of secondmalignan-
cies). The late cumulative complication rate was supe-
rior in the GELA cohort of 2837 patients treated with
chemotherapy without rituximab [15] and in a second
cohort of 372 patients who underwent HDT without
rituximab for relapsed/refractory aggressive NHL
[16]. It was also superior in the GITIL trial using rit-
uximab within a 7-month high dose schedule requiring
3 stem cell transplants [11].
Biol Blood Marrow Transplant 16:672-677, 2010 677Excellent Result of Up-front HDTwith Rituximab in Aggressive NHLIn summary, the present findings illustrate that
adding rituximab to HDT is feasible and safe and re-
sults in 55% CR and 74%OS at 5 years. Nevertheless,
adding rituximab to CHOP improved outcomes for
aggressive NHL, so all these results validate the inter-
est of our ongoing GOELAMS 075 study, a random-
ized prospective trial comparing HDT plus
rituximab followed by ASCT to R-CHOP14 (clinical
trial registration number NCT00561379).ACKNOWLEDGMENTS
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